TYRA
Tyra Biosciences, Inc.
Biotechnology
Market Cap$1.77B
5Y Perf.+87.0%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
TYRA vs KROS vs IMVT vs CRL
Revenue, margins, valuation, and 5-year total return — side by side.
KROS
Keros Therapeutics, Inc.
Biotechnology
Market Cap$433M
5Y Perf.-70.6%
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.53B
5Y Perf.+213.2%
CRL
Charles River Laboratories International, Inc.
Medical - Diagnostics & Research
Market Cap$8.98B
5Y Perf.-55.9%
TYRA vs KROS vs IMVT vs CRL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | TYRA | KROS | IMVT | CRL |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Medical - Diagnostics & Research |
| Market Cap | $1.77B | $433M | $5.53B | $8.98B |
| Revenue (TTM) | $0.00 | $244M | $0.00 | $4.03B |
| Net Income (TTM) | $-120M | $87M | $-464M | $-185M |
| Gross Margin | — | 99.5% | — | 24.9% |
| Operating Margin | — | 28.9% | — | 11.8% |
| Forward P/E | — | 5.1x | — | 16.4x |
| Total Debt | $6M | $17M | $98K | $3.07B |
| Cash & Equiv. | $77M | $287M | $714M | $214M |
TYRA vs KROS vs IMVT vs CRL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
TYRA
KROS
IMVT
CRL
| Stock | Sep 21 | May 26 | Return |
|---|---|---|---|
| Tyra Biosciences, I… (TYRA) | 100 | 187.0 | +87.0% |
| Keros Therapeutics,… (KROS) | 100 | 29.4 | -70.6% |
| Immunovant, Inc. (IMVT) | 100 | 313.2 | +213.2% |
| Charles River Labor… (CRL) | 100 | 44.1 | -55.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TYRA vs KROS vs IMVT vs CRL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: KROS leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Tyra Biosciences, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
TYRA
Tyra Biosciences, Inc.
The Income Pick
TYRA is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.
- beta 0.75
- Lower volatility, beta 0.75, Low D/E 2.2%, current ratio 14.67x
- Beta 0.75, current ratio 14.67x
- Beta 0.75 vs CRL's 1.52, lower leverage
Best for: income & stability and sleep-well-at-night
KROS
Keros Therapeutics, Inc.
The Growth Play
KROS carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 67.7%, EPS growth 146.0%
- 67.7% revenue growth vs TYRA's -38.9%
- Lower P/E (5.1x vs 16.4x)
- 35.7% margin vs CRL's -4.6%
Best for: growth exposure
IMVT
Immunovant, Inc.
The Long-Run Compounder
IMVT is the clearest fit if your priority is long-term compounding.
- 173.6% 10Y total return vs CRL's 119.2%
Best for: long-term compounding
CRL
Charles River Laboratories International, Inc.
The Secondary Option
CRL lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | KROS | 67.7% revenue growth vs TYRA's -38.9% |
| Value | KROS | Lower P/E (5.1x vs 16.4x) |
| Quality / Margins | KROS | 35.7% margin vs CRL's -4.6% |
| Stability / Safety | TYRA | Beta 0.75 vs CRL's 1.52, lower leverage |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | TYRA | +260.4% vs KROS's -15.1% |
| Efficiency (ROA) | KROS | 13.3% ROA vs IMVT's -44.1% |
TYRA vs KROS vs IMVT vs CRL — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
Segment breakdown not available.
FY 2025
TYRA vs KROS vs IMVT vs CRL — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLKROSLAGGINGCRL
Who Leads Where
KROS leads in 3 of 6 categories
TYRA leads 1 • IMVT leads 0 • CRL leads 0 • 1 tied
Explore the data ↓CRLCharles River Laborat…
0leads
IMVTImmunovant, Inc.
0leads
TYRATyra Biosciences, Inc.
1leads
KROSKeros Therapeutics, I…
3leads
6 Total Categories
CATEGORYLEADERvs TYRAvs IMVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
KROS5/6
Valuation MetricsMultiples, price ratios, and targets
KROS4/5
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
KROS5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
TYRA4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
KROS leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CRL and IMVT operate at a comparable scale, with $4.0B and $0 in trailing revenue. KROS is the more profitable business, keeping 35.7% of every revenue dollar as net income compared to CRL's -4.6%. On growth, CRL holds the edge at +1.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | TYRATyra Biosciences,… | KROSKeros Therapeutic… | IMVTImmunovant, Inc. | CRLCharles River Lab… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $244M | $0 | $4.0B |
| EBITDAEarnings before interest/tax | -$132M | $72M | -$487M | $757M |
| Net IncomeAfter-tax profit | -$120M | $87M | -$464M | -$185M |
| Free Cash FlowCash after capex | -$95M | $106M | -$423M | $391M |
| Gross MarginGross profit ÷ Revenue | — | +99.5% | — | +24.9% |
| Operating MarginEBIT ÷ Revenue | — | +28.9% | — | +11.8% |
| Net MarginNet income ÷ Revenue | — | +35.7% | — | -4.6% |
| FCF MarginFCF ÷ Revenue | — | +43.4% | — | +9.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -87.3% | — | +1.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -32.6% | +66.7% | +19.7% | -160.0% |
KROS leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
KROS leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
On an enterprise value basis, KROS's 2.3x EV/EBITDA is more attractive than CRL's 13.0x.
| Metric | TYRATyra Biosciences,… | KROSKeros Therapeutic… | IMVTImmunovant, Inc. | CRLCharles River Lab… |
|---|---|---|---|---|
| Market CapShares × price | $1.8B | $433M | $5.5B | $9.0B |
| Enterprise ValueMkt cap + debt − cash | $1.7B | $163M | $4.8B | $11.8B |
| Trailing P/EPrice ÷ TTM EPS | -16.37x | 5.06x | -9.97x | -62.52x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 16.42x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 2.26x | — | 12.98x |
| Price / SalesMarket cap ÷ Revenue | — | 1.78x | — | 2.24x |
| Price / BookPrice ÷ Book value/share | 7.57x | 1.45x | 5.83x | 2.81x |
| Price / FCFMarket cap ÷ FCF | — | 4.09x | — | 17.31x |
KROS leads this category, winning 4 of 5 comparable metrics.
Profitability & Efficiency
KROS leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
KROS delivers a 14.3% return on equity — every $100 of shareholder capital generates $14 in annual profit, vs $-47 for IMVT. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to CRL's 0.95x. On the Piotroski fundamental quality scale (0–9), KROS scores 5/9 vs TYRA's 1/9, reflecting solid financial health.
| Metric | TYRATyra Biosciences,… | KROSKeros Therapeutic… | IMVTImmunovant, Inc. | CRLCharles River Lab… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -41.2% | +14.3% | -47.1% | -5.7% |
| ROA (TTM)Return on assets | -38.4% | +13.3% | -44.1% | -2.5% |
| ROICReturn on invested capital | -44.8% | +167.9% | — | +6.3% |
| ROCEReturn on capital employed | -43.3% | +15.6% | -66.1% | +8.1% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 5 | 2 | 4 |
| Debt / EquityFinancial leverage | 0.02x | 0.06x | 0.00x | 0.95x |
| Net DebtTotal debt minus cash | -$72M | -$271M | -$714M | $2.9B |
| Cash & Equiv.Liquid assets | $77M | $287M | $714M | $214M |
| Total DebtShort + long-term debt | $6M | $17M | $98,000 | $3.1B |
| Interest CoverageEBIT ÷ Interest expense | — | — | — | 6.38x |
KROS leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
TYRA leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $16,241 today (with dividends reinvested), compared to $2,192 for KROS. Over the past 12 months, TYRA leads with a +260.4% total return vs KROS's -15.1%. The 3-year compound annual growth rate (CAGR) favors TYRA at 34.6% vs KROS's -35.4% — a key indicator of consistent wealth creation.
| Metric | TYRATyra Biosciences,… | KROSKeros Therapeutic… | IMVTImmunovant, Inc. | CRLCharles River Lab… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +22.8% | -37.2% | +5.1% | -10.1% |
| 1-Year ReturnPast 12 months | +260.4% | -15.1% | +96.1% | +32.8% |
| 3-Year ReturnCumulative with dividends | +143.7% | -73.0% | +40.9% | -4.2% |
| 5-Year ReturnCumulative with dividends | +26.5% | -78.1% | +62.4% | -46.9% |
| 10-Year ReturnCumulative with dividends | +26.5% | -42.0% | +173.6% | +119.2% |
| CAGR (3Y)Annualised 3-year return | +34.6% | -35.4% | +12.1% | -1.4% |
TYRA leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — TYRA and IMVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
TYRA is the less volatile stock with a 0.75 beta — it tends to amplify market swings less than CRL's 1.52 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 90.5% from its 52-week high vs KROS's 51.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | TYRATyra Biosciences,… | KROSKeros Therapeutic… | IMVTImmunovant, Inc. | CRLCharles River Lab… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.75x | 1.03x | 1.37x | 1.52x |
| 52-Week HighHighest price in past year | $40.65 | $22.55 | $30.09 | $228.88 |
| 52-Week LowLowest price in past year | $8.75 | $10.41 | $13.36 | $131.30 |
| % of 52W HighCurrent price vs 52-week peak | +80.9% | +51.6% | +90.5% | +79.5% |
| RSI (14)Momentum oscillator 0–100 | 43.1 | 51.8 | 60.2 | 57.2 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 409K | 1.4M | 806K |
Evenly matched — TYRA and IMVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: TYRA as "Buy", KROS as "Buy", IMVT as "Buy", CRL as "Buy". Consensus price targets imply 781.4% upside for KROS (target: $103) vs 12.9% for CRL (target: $205).
| Metric | TYRATyra Biosciences,… | KROSKeros Therapeutic… | IMVTImmunovant, Inc. | CRLCharles River Lab… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $50.50 | $102.60 | $45.50 | $205.43 |
| # AnalystsCovering analysts | 7 | 16 | 23 | 36 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | 1 |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +86.6% | 0.0% | +4.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
KROS leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). TYRA leads in 1 (Total Returns). 1 tied.
Best OverallKeros Therapeutics, Inc. (KROS)Leads 3 of 6 categories
Loading custom metrics...
TYRA vs KROS vs IMVT vs CRL: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is TYRA or KROS or IMVT or CRL a better buy right now?
For growth investors, Keros Therapeutics, Inc.
(KROS) is the stronger pick with 67. 7% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). Keros Therapeutics, Inc. (KROS) offers the better valuation at 5. 1x trailing P/E, making it the more compelling value choice. Analysts rate Tyra Biosciences, Inc. (TYRA) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TYRA or KROS or IMVT or CRL?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +62. 4%, compared to -78. 1% for Keros Therapeutics, Inc. (KROS). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus KROS's -42. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TYRA or KROS or IMVT or CRL?
By beta (market sensitivity over 5 years), Tyra Biosciences, Inc.
(TYRA) is the lower-risk stock at 0. 75β versus Charles River Laboratories International, Inc. 's 1. 52β — meaning CRL is approximately 101% more volatile than TYRA relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 95% for Charles River Laboratories International, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — TYRA or KROS or IMVT or CRL?
By revenue growth (latest reported year), Keros Therapeutics, Inc.
(KROS) is pulling ahead at 67. 7% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: Keros Therapeutics, Inc. grew EPS 146. 0% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — TYRA or KROS or IMVT or CRL?
Keros Therapeutics, Inc.
(KROS) is the more profitable company, earning 35. 7% net margin versus -3. 6% for Charles River Laboratories International, Inc. — meaning it keeps 35. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KROS leads at 28. 9% versus 0. 0% for IMVT. At the gross margin level — before operating expenses — KROS leads at 99. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is TYRA or KROS or IMVT or CRL more undervalued right now?
Analyst consensus price targets imply the most upside for KROS: 781.
4% to $102. 60.
07Which pays a better dividend — TYRA or KROS or IMVT or CRL?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is TYRA or KROS or IMVT or CRL better for a retirement portfolio?
For long-horizon retirement investors, Tyra Biosciences, Inc.
(TYRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 75)). Charles River Laboratories International, Inc. (CRL) carries a higher beta of 1. 52 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TYRA: +26. 5%, CRL: +119. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between TYRA and KROS and IMVT and CRL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: TYRA is a small-cap quality compounder stock; KROS is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock; CRL is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.